3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gastrointestinal
1
Breast
1
Conditions
Myeloproliferative Disorders
5
Primary Myelofibrosis
4
Carcinoma, Non-Small-Cell Lung
4
Hematologic Neoplasms
3
Thrombocytosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polycythemia Vera
1
Myelodysplastic Syndromes
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Acute
1
Hodgkin Disease
1
Hematologic Diseases
1
Gastrointestinal Neoplasms
1
Breast Neoplasms
1
Interventions
Oxaliplatin
10
Capecitabine
9
Cisplatin
8
Fluorouracil
5
Leucovorin
4
Bevacizumab
4
tegafur-gimeracil-oteracil
3
pemigatinib
3
atezolizumab
3
Nivolumab
3
trebananib
2
ponatinib
2
pembrolizumab
2
avelumab
2
apatinib
2
alectinib
2
XELOX
2
Standard of Care
2
S 1 (combination)
2
Radiotherapy
2
Radiosurgery
2
Ocoxin
2
Irinotecan
2
Ipilimumab
2
Gemcitabine
2
Folfox protocol
2
Everolimus
2
Erlotinib Hydrochloride
2
Acupuncture Therapy
2
zanidatamab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Gastrointestinal Neoplasms
×
itacitinib
×
Clear all
NCT04591431
2023-10-03
ROME
Fondazione per la Medicina Personalizzata
Phase 2
Unknown
400 enrolled